Ignite Creation Date:
2025-12-25 @ 3:55 AM
Ignite Modification Date:
2025-12-26 @ 2:46 AM
Study NCT ID:
NCT04767802
Status:
COMPLETED
Last Update Posted:
2024-03-18
First Post:
2021-02-18
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011087', 'term': 'Polycythemia Vera'}], 'ancestors': [{'id': 'D019046', 'term': 'Bone Marrow Neoplasms'}, {'id': 'D019337', 'term': 'Hematologic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001855', 'term': 'Bone Marrow Diseases'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D009196', 'term': 'Myeloproliferative Disorders'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 20}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-02-02', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-03', 'dispFirstSubmitDate': '2024-03-13', 'completionDateStruct': {'date': '2023-03-15', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-03-14', 'studyFirstSubmitDate': '2021-02-18', 'studyFirstSubmitQcDate': '2021-02-22', 'dispFirstPostDateStruct': {'date': '2024-03-15', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2024-03-18', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-02-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-03-15', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': "Evaluate PTG-300's efficacy in subjects with PV and baseline elevated hematocrit.", 'timeFrame': 'Estimate the proportion of subject with a hematocrit less than 45% at Week 16', 'description': 'Proportion of subjects with hematocrit \\<45%'}], 'secondaryOutcomes': [{'measure': 'Safety of PTG-300', 'timeFrame': 'Week 52', 'description': 'Proportion of Subjects Treatment-Emergent Adverse Events'}]}, 'oversightModule': {'isUsExport': True, 'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['PV'], 'conditions': ['Polycythemia Vera']}, 'descriptionModule': {'briefSummary': 'This is an open label, single arm trial of PTG-300 in subjects with PV who are newly diagnosed or for whom current therapy is not sufficient to control their hematocrit and have hematocrit \\>48% prior to dosing. The PTG-300 dose and schedule may be adjusted every 2 to 4 weeks to maintain hematocrit \\<45% with a target of \\<43%. Subjects may receive PTG-300 treatment for up to 52 weeks.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Known diagnosis of polycythemia vera.\n2. Hematocrit \\>48% before dosing.\n3. Evidence of hematocrit \\>48% three or more times in the 28 weeks before dosing or five or more times in 52 weeks before dosing (except for newly diagnosed patients).\n4. Clinically reasonable alternative causes for erythrocytosis have been evaluated and excluded.\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.\n\nExclusion Criteria:\n\n1. Clinically significant thrombosis (e.g., deep vein thrombosis or splenic vein thrombosis) within 3 months of Screening.\n2. Active or chronic bleeding within 4 weeks of Screening.\n3. Meets the criteria for post-PV myelofibrosis as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).\n4. Infection requiring hospitalization or intravenous antimicrobial therapy, or opportunistic infection within 3 months of dosing; any infection requiring systemic antimicrobial therapy within 4 weeks of dosing. Prophylactic antibiotics are allowed.\n5. Any serious or unstable medical or psychiatric condition that would prevent, (as judged by the Investigator) the subject from properly providing informed consent or any condition which would jeopardize compliance with the study.\n6. Known primary or secondary immunodeficiency.\n7. Known positive for active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.\n8. Any surgical procedure requiring general anesthesia within 1 month prior to Screening or planned elective surgery during the study.\n9. History of invasive malignancies within the last 2 years, except non-melanoma skin cancer and localized curatively treated prostate cancer or cervical cancer.\n10. Current or recent history of alcohol dependence or illicit drug use within 1 year prior to Screening.'}, 'identificationModule': {'nctId': 'NCT04767802', 'acronym': 'PACIFIC', 'briefTitle': 'PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit', 'organization': {'class': 'INDUSTRY', 'fullName': 'Protagonist Therapeutics, Inc.'}, 'officialTitle': 'A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit (PACIFIC)', 'orgStudyIdInfo': {'id': 'PTG-300-08'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'PTG-300', 'description': "Evaluate PTG-300's efficacy and safety in subjects with PV and baseline elevated hematocrit.", 'interventionNames': ['Drug: PTG-300']}], 'interventions': [{'name': 'PTG-300', 'type': 'DRUG', 'otherNames': ['Rusfertide'], 'description': 'Hepcidin mimetic', 'armGroupLabels': ['PTG-300']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Johor Bahru', 'state': 'Johor', 'country': 'Malaysia', 'facility': 'Hospital Sultanah Aminah', 'geoPoint': {'lat': 1.4655, 'lon': 103.7578}}, {'city': 'Kota Bharu', 'state': 'Kelantan', 'country': 'Malaysia', 'facility': 'Hospital Raja Perempuan Zainab', 'geoPoint': {'lat': 6.12361, 'lon': 102.24333}}, {'city': 'Ipoh', 'state': 'Perak', 'country': 'Malaysia', 'facility': 'Hospital Raja Permaisuki Bainun', 'geoPoint': {'lat': 4.5841, 'lon': 101.0829}}, {'city': 'Kuching', 'state': 'Sarawak', 'country': 'Malaysia', 'facility': 'Hospital Umum Sarawak', 'geoPoint': {'lat': 1.55, 'lon': 110.33333}}, {'city': 'Ampang', 'state': 'Selangor', 'country': 'Malaysia', 'facility': 'Hospital Ampang'}, {'city': 'Incheon', 'country': 'South Korea', 'facility': 'Gachon University Medical Center', 'geoPoint': {'lat': 37.45646, 'lon': 126.70515}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': "Seoul St. Mary's Catholic University Hospital", 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Protagonist Therapeutics, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}